Full Coverage

NeoPharm Enrolls First Patient in Phase I Trial for Patients with Metastatic Solid Cancer

ad-hoc-news.de
May 21, 2008
        
Story Timeline:  197 days

NeoPharm Enrolls First Patient in Phase I Trial for Patients with Metastatic Solid Cancer NeoPharm Enrolls First Patient in Phase I Trial for Patients with Metastatic Solid CancerLAKE BLUFF, Ill.IL-NEOPHARM LAKE BLUFF, Ill.--(BUSINESS WIRE)-- NeoPharm, Inc. (NASDAQ:NEOL) today announced that it... [read full story]                    

Add Comment
Latest article on this story:

NeoPharm signs LoI with Siro ClinPharm

 pharmaceutical-business-review.com May 24, 2008
First article on this story:

NeoPharm Enrolls First Patient in Phase I Trial for Patients with Metastatic Solid Cancer...

 yahoo.com May 21, 2008
Selected publications with coverage of this story:
redorbit.com pharmaceutical-business-review.com medicalnewstoday.com yahoo.com earthtimes.org ad-hoc-news.de euroinvestor.co.uk finanznachrichten.de
RELATED
Found 8 documents:

NeoPharm signs LoI with Siro ClinPharm

pharmaceutical-business-review.com
May 24, 2008
        

NeoPharm has signed a letter of intent with Siro ClinPharm USA with regard to Siro's engagement to oversee a planned confirmatory Phase III trial for its drug product candidate Cintredekin Besudotox, for the treatment of patients suffering from recurrent glioblastoma multiforme.

NeoPharm Enrolls First Patient In Phase I Trial For Patients With Metastatic Solid Cancer

medicalnewstoday.com
May 23, 2008
        

NeoPharm, Inc. (NASDAQ:NEOL) announced that it has enrolled its first patient in its Phase I clinical trial for LE-DT, a novel, proprietary liposomal delivery system of docetaxel, the active ingredient of Taxotere®, which is used for the treatment of patients with metastatic solid cancer.

NeoPharm initiates enrollment in Phase I cancer trial

pharmaceutical-business-review.com
May 23, 2008
        

NeoPharm has enrolled its first patient in its Phase I clinical trial for LE-DT, a novel, proprietary liposomal delivery system of docetaxel, the active ingredient of Taxotere, which is used for the treatment of patients with metastatic solid cancer.

NeoPharm Initiates Enrollment in Phase I Cancer Trial

redorbit.com
May 22, 2008
        

NeoPharm has enrolled its first patient in its Phase I clinical trial for LE-DT, a novel, proprietary liposomal delivery system of docetaxel, the active ingredient of Taxotere, which is used for the treatment of patients with metastatic solid cancer.

                   

NeoPharm Announces Execution of a Letter of Intent with SIRO ClinPharm for a planned Confirmatory...

finanznachrichten.de
May 22, 2008
        

NeoPharm, Inc. (NASDAQ: NEOL) today announced that it has signed a letter of intent with SIRO ClinPharm USA (“SIRO“_) with regard to SIRO's engagement to oversee a planned confirmatory Phase III trial for its drug product candidate Cintredekin Besudotox (IL13-PE38QQR) (“IL-13“_), for the...

                   

NeoPharm Announces Execution of a Letter of Intent with SIRO ClinPharm for a planned Confirmatory...

yahoo.com
May 22, 2008
        

LAKE BLUFF, Ill.--(BUSINESS WIRE)--NeoPharm, Inc. (NASDAQ: NEOL - News ) today announced that it has signed a letter of intent with SIRO ClinPharm USA (“SIRO”) with regard to SIRO’s engagement to oversee a planned confirmatory Phase III trial for its drug product candidate Cintredekin Besudotox...

                   

NeoPharm Announces Execution of a Letter of Intent with SIRO ClinPharm for a planned Confirmatory...

earthtimes.org
May 22, 2008
        

LAKE BLUFF, Ill. - (Business Wire) NeoPharm, Inc. (NASDAQ: NEOL) today announced that it has signed a letter of intent with SIRO ClinPharm USA (“SIRO”) with regard to SIRO’s engagement to oversee a planned confirmatory Phase III trial for its drug product candidate Cintredekin Besudotox...

NeoPharm Enrolls First Patient in Phase I Trial for Patients with Metastatic Solid Cancer...

yahoo.com
May 21, 2008
        

LAKE BLUFF, Ill.----NeoPharm, Inc. today announced that it has enrolled its first patient in its Phase I clinical trial for LE-DT, a novel, proprietary liposomal delivery system of docetaxel, the active ingredient of Taxotere®, which is used for the treatment of patients with metastatic solid...